skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Reduced peripheral activity leading to hepato‐preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

Journal Article · · Diabetes, Obesity and Metabolism
DOI:https://doi.org/10.1111/dom.12753· OSTI ID:1401715
 [1];  [1];  [1];  [2];  [2];  [3];  [4];  [5];  [4];  [5];  [4];  [3];  [4];  [4];  [4];  [4]
  1. Veterans Affairs San Diego Healthcare System San Diego CA USA, Department of Medicine, Division of Endocrinology and Metabolism, University of California San Diego CA USA
  2. Veterans Affairs San Diego Healthcare System San Diego CA USA
  3. Department of Medicine, Division of Endocrinology and Metabolism, University of California San Diego CA USA
  4. Eli Lilly and Company Indianapolis IN USA
  5. Eli Lilly and Company Singapore Singapore

Aims Basal insulin peglispro ( BIL ), a novel PEGylated basal insulin with a large hydrodynamic size, has a delayed absorption and reduced clearance that prolongs the duration of action. The current study compared the effects of BIL and insulin glargine ( GL ) on endogenous glucose production ( EGP ), glucose disposal rate ( GDR ) and lipolysis in patients with type 1 diabetes. Materials and Methods This was a randomized, open‐label, four‐period, crossover study. Patients received intravenous infusions of BIL and GL , each at two dose levels selected for partial and maximal suppression of EGP , during an 8 to 10 h euglycemic clamp procedure with d ‐[3‐ 3 H] glucose. Results Following correction for equivalent human insulin concentrations ( EHIC ), low‐dose GL infusion resulted in similar EGP at the end of the clamp compared to low‐dose BIL infusion ( GL / BIL ratio of 1.03) but a higher GDR ( GL / BIL ratio of 2.42), indicating similar hepatic activity but attenuated peripheral activity of BIL . Consistent with this, the EHIC ‐corrected GDR / EGP at the end of the clamp was 1.72‐fold greater for GL than BIL following low‐dose administration. At the lower dose of BIL and GL (concentrations in the therapeutic range), BIL produced less suppression of lipolysis compared with GL as indicated by free fatty acid and glycerol levels at the end of the clamp. Conclusions Compared with GL , BIL restored the hepato‐peripheral insulin action gradient seen in normal physiology via its peripherally restricted action on target tissues related to carbohydrate and lipid metabolism.

Sponsoring Organization:
USDOE
OSTI ID:
1401715
Journal Information:
Diabetes, Obesity and Metabolism, Journal Name: Diabetes, Obesity and Metabolism Vol. 18 Journal Issue: S2; ISSN 1462-8902
Publisher:
Wiley-BlackwellCopyright Statement
Country of Publication:
Country unknown/Code not available
Language:
English
Citation Metrics:
Cited by: 12 works
Citation information provided by
Web of Science

References (22)

A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1 journal October 2016
Insulin's direct effects on the liver dominate the control of hepatic glucose production journal January 2006
A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes journal October 2012
Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 Diabetes journal June 2015
Insulin Levels After Portal and Systemic Insulin Infusion Differ in a Dose-Dependent Fashion journal December 1998
Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects: Journal of Clinical Pharmacology journal February 2014
"Normal" Insulin Secretion: The Goal of Artificial Insulin Delivery Systems? journal March 1980
Intravenous Glargine and Regular Insulin Have Similar Effects on Endogenous Glucose Output and Peripheral Activation/Deactivation Kinetic Profiles journal September 2002
Pulsatile Insulin Secretion Dictates Systemic Insulin Delivery by Regulating Hepatic Insulin Extraction In Humans journal May 2005
Estimation of Endogenous Glucose Production During Hyperinsulinemic-Euglycemic Glucose Clamps: Comparison of Unlabeled and Labeled Exogenous Glucose Infusates journal August 1987
Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4 journal June 2016
Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM journal October 2013
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog journal March 2016
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes journal October 2016
Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3 journal August 2016
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5 journal November 2015
A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial journal October 2016
Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism journal October 2013
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials journal September 2016
Hepatoselectivity and the evolution of insulin journal May 2013
Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial journal August 2016
Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study journal November 2012

Similar Records

Interactions of glucagon and free fatty acids with insulin in control of glucose metabolism
Journal Article · Sat Sep 01 00:00:00 EDT 1990 · Metabolism, Clinical and Experimental; (USA) · OSTI ID:1401715

Peripheral effects of insulin dominate suppression of fasting hepatic glucose production
Journal Article · Fri Jun 01 00:00:00 EDT 1990 · American Journal of Physiology; (USA) · OSTI ID:1401715

VMAT optimization with dynamic collimator rotation
Journal Article · Thu May 03 00:00:00 EDT 2018 · Medical Physics · OSTI ID:1401715

Related Subjects